Inrebic, a new drug for myelofibrosis, has settled down in Big 5. According to related industries, Korea BMS Pharmaceutical's myelofibrosis treatment Inrebic passed the Drug Committee (DC) of the big five medical institutions, including SMC, Seoul National University Hospital, Seoul St. Mary's Hospital, Asan Medical Center, and Severance Hospital. Since being registered as an insurance benefit in June, it has been steadily expanding its prescription area.

Inrebic was approved in Korea in April of last year for the treatment of splenomegaly or symptoms related to primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after essential thrombocythemia in adult patients previously t